Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
BJ Ball, CA Famulare, EM Stein, MS Tallman… - Blood …, 2020 - ashpublications.org
Blood advances, 2020•ashpublications.org
Key Points Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and
HMAs have an ORR of 59% with 63% of responders proceeding to transplant. Allogeneic
stem cell transplantation after treatment with venetoclax in combination with HMA is
associated with prolonged survival.
HMAs have an ORR of 59% with 63% of responders proceeding to transplant. Allogeneic
stem cell transplantation after treatment with venetoclax in combination with HMA is
associated with prolonged survival.
Key Points
- Treatment-naive and relapsed/refractory MDS patients receiving venetoclax and HMAs have an ORR of 59% with 63% of responders proceeding to transplant.
- Allogeneic stem cell transplantation after treatment with venetoclax in combination with HMA is associated with prolonged survival.
ashpublications.org